This study shows the long-term updated outcomes of a multicenter retrospective study which analyzed 843 patients with myelodysplastic syndrome (MDS) who underwent transplantation with an HLA-identical sibling donor with either reduced-intensity conditioning (RIC) in 213 patients, or standard myeloablative conditioning (MAC) in 630 patients. In multivariate analysis, the 13-year relapse rate was significantly increased after RIC (31% after MAC vs 48% in RIC; HR, 1.5; 95% CI, 1.1-1.9; P = 0.04), but with no differences in overall survival (OS) (30% after MAC vs 27% in RIC; P = 0.4) and PFS (29 vs 21%, respectively, P = 0.3). Non-relapse mortality was higher in MAC (40 vs 31%; P = 0.1), especially in patients older than 50 years (50 vs 33%, P o0.01). In addition, long-term follow-up confirms the importance of other variables on 13-year OS, mainly MDS risk category, disease phase, cytogenetics and receiving a high donor cell dose, irrespective of the conditioning regimen used.
Over the last decade, a plethora of data has been published on the potential role of allogeneic hematopoietic stem cell transplantation (AlloHSCT) in patients with MDS. Due to large heterogeneity of diseases classified under the MDS, studies have attempted to identify the MDS risk groups in which AlloHSCT is most indicated, the optimal moment for proceeding to such treatment, and patient characteristics/comorbidities that may modify its estimated risk/benefit ratio. [1] [2] [3] [4] [5] [6] With respect to the transplantation procedure itself, several donor types and HSC sources are currently available. Finally, the intensity of the conditioning regimen used is an area of special interest. In this respect, the dozens of different conditioning regimens published in MDS are broadly classified as conventional high-dose MAC and RIC regimens. 7 In an effort to analyze the impact of RIC regimens in MDS, the Chronic Malignancies Working Party of the European Blood and Marrow Transplantation Group performed a retrospective study whose results were published in 2006. 8 The study included AlloHSCT from HLA-identical siblings in whom the conditioning regimen used was known, and, at the time of publication, the median follow-up in survivors was 3-4 years in RIC and MAC recipients, respectively. With the aim of improving the information which could be derived from the initial manuscript, we herein report the long-term outcomes of these same patients 10 years later.
MATERIALS AND METHODS

Patient and transplantation characteristics
Details of the 843 patients included in the study from 128 centers can be found in the original report. 8 Briefly, only patients who underwent a first allogeneic hematopoietic stem cell transplantation (AlloHSCT) with a welldefined conditioning regimen between January 1997 and December 2001 from HLA-genoidentical siblings and who were registered in the European Blood and Marrow Transplantation Group registry were included in this analysis. As expected, baseline patient characteristics differed between both the study groups, especially the median recipient age at transplantation (45 years for standard myeloablative conditioning (MAC) and 56 years for reduced-intensity conditioning (RIC) recipients).
Statistical methods
Details of the statistical methods used in the current study can be found as Supplementary Online Material. The median follow-up in survivors was now 10.5 and 13 years in RIC and MAC recipients, respectively. Thus, the outcomes were now analyzed at 13-year follow-up, when the median age 
RESULTS AND DISCUSSION
The 13-year incidence of NRM was 40% and 31% in the MAC and RIC groups, respectively (P = 0.1) ( Table 1) . In multivariate analysis, the variables that were associated with an increased 13-year NRM were: (1) use of MAC in patient 450 years old (P o0.01); while (2) RIC in patients age ⩽ 50 years showed a trend toward lower NRM (P = 0.1); (3) low CD34+ cell dose infused (P o 0.01); (4) not being in first CR at transplant (P o 0.01); while (5) BM as stem cell source showed a trend toward higher NRM (P = 0.1). The cumulative incidence of NRM in patients 450 years old who received RIC or MAC was 33% and 50%, respectively (P = 0.01 for the comparison of these two categories), while in those ⩽ 50 years old the NRM was 24% and 36%, respectively (P = 0.1 for the comparison of these two categories) (shown in Figure 1 ).
The 13-year incidence of disease relapse or progression was 31% and 48% in the MAC and RIC groups, respectively (P o0.01) ( Table 2 and Figure 2) . In multivariate analysis, the variables that were associated with an increased 13-year NRM were: (1) use of RIC (P = 0.04); (2) advanced disease risk/stage (Po 0.01); (3) in vivo T-cell depletion with ATG or alemtuzumab (P = 0.01); and (5) poor-risk cytogenetics (P o0.01).
As shown in Table 3 and Figure 3 , transplant conditioning group had no impact on the 13-year probabilities of OS and PFS; the 13-year OS was 30% in the MAC group and 27% in the RIC group (P = 0.4), while the PFS was 29 and 21%, respectively (P = 0.06). In multivariate analysis, variables that decreased OS were: (1) patient age450 years (P = 0.01); (2) not being in first CR at transplant (P o 0.01); (3) secondary AML vs MDS (P = 0.02); (4) poor-risk cytogenetics (P o0.01); and (5) low CD34+ cell dose infused (P o 0.01). These same variables had an impact on the 13-year PFS, as shown in detail in Table 3 .
Causes of death beyond +3 years (late deaths) Three hundred and two patients were alive and progression-free 3 years after AlloHSCT, 239 after MAC and 63 after RIC; 184 and 46, respectively, were alive and progression-free at +6 years; 150 and 38, respectively, were alive and progression-free at +9 years, and 100 and 16 patients, respectively, were alive and progression-free 13 years after AlloHSCT. There were 62 late deaths, 49 of these after MAC, 25 in years 3.01-6; 8 in years 6.01-9; and 16 deaths occurred beyond 9 years. Seventeen late deaths occurred after RIC, 10 in years 3.01-6; 2 in years 6.01-9; and 5 deaths occurred beyond 9 years.
The cause of late death was disease relapse in 10/49 (20%) late deaths in MAC recipients and 5/17 (29%) in RIC recipients. Of the deaths included under NRM (80% and 71% of late deaths, respectively), 13/49 (27%) were due to secondary cancers in MAC recipients and 4/17 (24%) in the RIC group; chronic GvHD (cGvHD) was the primary cause of death in 6 (12%) and 4 (24%) cases, respectively, while infection-related mortality without cGvHD occurred in 2 (4%) and 1 (6%) cases. A suspected infection in patients with cGvHD was the attributable cause of death in 11 Abbreviations: cGvHD = chronic GvHD; CI = confidence interval; CumInc = cumulative incidence; NRM = non-relapse mortality; OS = overall survival. a Patients were considered evaluable for cGvHD if they survived without disease progression at day +100.
b Cumulative incidence with disease progression as competing risk; Gray's univariate likelihood ratio test from COX model = log-rank from Kaplan-Meier. Long-term follow-up of RIC Abbreviations: AML = acute myeloid leukemia; ATG = anti-thymocyte globulin; CI = confidence interval; CR1 = first complete remission; HR = hazard ratio; MAC = standard myeloablative conditioning; Multi. = multivariate; NRM = non-relapse mortality; NS = not statistically significant, and thus results not shown; NTi = variables not tested separately in the multivariate analysis, since an interaction was identified between patient age group and conditioning regimen group on the risk of 13-year NRM, and thus a composite interaction covariable was created combining age (p50 years and 450 years) and conditioning intensity (RIC and MAC). This composite variable was not tested in the analyses of relapse; NTc = the variables response to chemotherapy and disease risk showed strong collinearity on the risk of 13-year relapse, and thus in the multivariate analysis only risk was introduced as a covariable since it is a more standardized variable for defining the disease status and stage at the time of transplantation and the associated risk of transplant failure due to relapse or progression; Probab. = probability; RIC = reduced-intensity conditioning; TCD = T-cell depletion; Univ. = univariate; -= not analyzed (left in blank) since the Pvalue was above 0.05. The number of patients for some variables does not equal 843 patients due to those cases who had an 'unknown' value for that variable. Thus the COX model contains a category for 'unknown' to avoid loss of information; the individual P-values denote the P-values of the given contrasts to the reference category. For clarity sake the 'unknown' categories as well as the non-significant risk factors have been omitted from the table. Response to AML-type chemotherapy refers to whether CR was achieved with AML-type chemotherapy prior to the transplant conditioning or if the patient did not receive such treatment ('untreated' group. The 'treated, not in first CR1' group included patients in second or later CR, and those who were refractory to chemotherapy or in partial response or had progressive disease after chemotherapy. e Disease risk/stage at transplant was defined as early risk/stage ( o5% marrow blasts: untreated Refractory Anemia or Refractory Anemia with Ring Sideroblasts; or those with Refractory Anemia with excess blasts (RAEB) types 1 and 2, those with the old category of RAEB in transformation and those with secondary or therapy-related AML in CR1 with intensive chemotherapy), and advanced risk/phase (45% marrow blasts at transplantation or beyond CR1). f CD34+ cell dose infused = refers to the cell dose infused below and above the median for each stem cell (classified as low and high cell dose infused, respectively); CD34+ cells in peripheral blood stem cell recipients (median CD34+ cells = 5.5 × 106/kg recipient weight) or total nucleated cells for bone marrow recipients (median = 2.2 × 108/kg recipient weight).
Long-term follow-up of RIC(22%) and 2 (12%) of MAC and RIC late deaths, respectively, while the cause was unknown in 7 and 1 cases, respectively.
Despite the numerous studies published on the results of AlloHSCT in patients with MDS and secondary AML, there are few reporting long-term outcomes. [9] [10] [11] [12] [13] [14] Our aim was to use the same patient cohorts used in the initial study published a decade ago and update their outcome, thus fulfilling an essential but often overlooked responsibility when publishing results of HSCT with a relatively short follow-up (3 years in the initial manuscript); that is, updating the outcome of those patients a decade later. Long-term survival is similar after RIC and MAC in MDS transplanted from HLA-identical siblings. Patients who are transplanted in an early disease stage and with non-poor risk cytogenetics can expect 13-year OS of more than 40%, after RIC or MAC. However, as expected, those with advanced disease status and with poor cytogenetics have poor long-term outcomes, regardless of the conditioning regimen. Among those who were alive and diseasefree 3 years post AlloHSCT, relapse was an uncommon cause of late death after both regimens, while NRM accounted for 470% of late deaths, and among these second cancers accounted for more late deaths than disease relapse.
Wingard et al. 12 published in 2011, the largest study to date on the long-term survival after AlloHSCT. The study included 930 patients with MDS and secondary or therapy-related AML reported to the Center for International Blood and Marrow Transplant Research up to 2003 and were alive and disease-free The number of patients for some variables does not equal 843 patients due to those cases who had an 'unknown' value for that variable. Thus the COX model contains a category for 'unknown' to avoid loss of information; the individual P-values denote the P-values of the given contrasts to the reference category. For clarity sake the 'unknown' categories as well as the non-significant risk factors have been omitted from the table. b A HRo1.0 indicates that the variable leads to a reduction in mortality or transplant failure, and thus an increase of OS or PFS, respectively, while values above 1.0 indicate that it leads to an increase in mortality or transplant failure, and thus to a reduction of OS or PFS, respectively. c Reference group.
d Response to AML-type chemotherapy refers to whether CR was achieved with AML-type chemotherapy prior to the transplant conditioning or if the patient did not receive such treatment ('untreated' group. The 'treated, not in first CR1' group included patients in second or later CR, and those who were refractory to chemotherapy or in partial response or had progressive disease after chemotherapy. e Disease Risk/stage at transplant was defined as early risk/stage (o5% marrow blasts: untreated Refractory Anemia or Refractory Anemia with Ring Sideroblasts; or those with Refractory Anemia with excess blasts (RAEB) types 1 and 2, those with the old category of RAEB in transformation and those with secondary or therapy-related AML in CR1 with intensive chemotherapy), and Advanced Risk/phase (45% marrow blasts at transplantation or beyond CR1).
f CD34+ cell dose infused = refers to the cell dose infused below and above the median for each stem cell (classified as low and high cell dose infused, respectively); CD34+ cells in peripheral blood stem cell recipients (median CD34+ cells = 5.5 × 106/kg recipient weight) or total nucleated cells for bone marrow recipients (median = 2.2 × 108/kg recipient weight).
Long-term follow-up of RIC2 years after a MAC from any donor and stem source. Disease relapse was the cause of 34-43% of late deaths, while NRM due to infection or GvHD caused another 30-40% of these deaths. However, RIC transplants were not included, and late deaths were defined as those occurring beyond 2 years after AlloHSCT, thus explaining the differences observed with our study.
The current study has the limitations common to all retrospective registry-based studies, including the lack of disease-and patient-related information which is currently considered crucial for deciding if and when a patient with MDS should undergo an AlloHSCT when an HLA-identical sibling is available; among the disease-related variables, the revised international prognostic system is of major importance, [15] [16] [17] [18] while among patient-related variables, the age-adjusted hematopoietic cell transplant comorbidity index and the patients' biological age/performance status are of major importance. [19] [20] [21] [22] [23] We must emphasize that recently enrollment in a phase III randomized trial comparing RIC vs MAC in patients with MDS (N = 54) or AML (N = 218) was stopped early due to a higher-thanacceptable benefit of MAC as assessed by an independent Data Review Committee. 24 Among 272 patients enrolled, 135 received MAC and 137 received RIC regimens; although at 18 months follow-up the interim results confirmed that RIC resulted in higher relapse rates and lower NRM compared to MAC, there was a large advantage in RFS for patients receiving MAC, and this difference was mainly due to a very high relapse rate in patients with MDS. Data from this trial support MAC as the standard of care for patients able to receive it. Of course, no long-term data is available from this recent trial. 24 However, as previously emphasized, most patients with MDS are not candidates for MAC strategies.
Notwithstanding its caveats, the current long-term results will surely be useful by documenting the minimally expected outcomes after AlloHSCT in MDS. These results, however, cannot be extrapolated to other donor types, such as related haploidentical HSCT.
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